Digital Transformation Reshapes the Pharmaceutical Industry: AI Accelerates Drug R&D and Digital Tools Drive Marketing Innovation
Contrary to the traditional perception of pharmaceutical companies as large, cumbersome entities with bloated organizational structures and functions, these enterprises are in fact leveraging digital tools to transform their R&D and marketing approaches. The aim is to streamline organizational structures and workflows, accelerate drug time-to-market, and enhance operational efficiency for smoother business operations.
Pharmaceutical companies’ adoption of digital tools is reflected in three aspects: technology, data, and processes. By leveraging technologies such as cloud computing, big data, the Internet of Things (IoT), the internet, and artificial intelligence (AI), they innovate drug R&D models, reducing the time-to-market and resource costs for new drugs; efficiently acquire and manage data to provide data support for internal management and external marketing; and optimize organizational structures and workflows to build an excellent management system.
New technologies and applications are emerging in profusion, including sensors, the Internet of Things (IoT), artificial intelligence (AI), 3D printing, and big data. Humanity is entering the era of the Third Technological Revolution, during which productive forces and relations of production are being dismantled and reconfigured.
The foundation of the pharmaceutical industry lies in the successful commercialization of specific technologies or technological categories, such as screening drug-like compounds from tens of thousands of candidates, extensively validating their druggability through rigorous experimentation, and ultimately transforming them into products that benefit patients. The commercialization of technology has driven significant prosperity in the pharmaceutical sector, which is currently undergoing profound transformation fueled by emerging technologies.
We have observed that many pharmaceutical companies can establish a solid market position with just one drug, which serves as an example of successful commercialization of technology. For instance, AbbVie, the pioneer in developing adalimumab, had its product approved for marketing in 2007, achieving $3 billion in sales revenue in the first year. It subsequently maintained rapid growth, with annual sales of adalimumab reaching $18.427 billion in 2017, accounting for 65% of its total revenue.
Societal demand for healthcare products and services is also compelling the industry to continuously leverage new technologies. Demographic shifts—such as population aging and declining birth rates—are driving up the need for chronic disease management and rehabilitative care. With severe deficits in national healthcare budgets, countries are seeking diverse cost-containment strategies to meet the public’s basic healthcare coverage needs, while commercial health insurers also require prudent budget control to ensure profitability.
On the other hand, as income levels rise and public health awareness increases, people are willing to invest more in healthcare, seeking more precise, personalized, and comfortable medical services. There is an urgent need to establish a “value-based healthcare” service system that is patient-centered and user-centered.
Driven by new technologies and their applications, the healthcare industry is delivering higher-quality products and services while enhancing accessibility through more efficient distribution systems. The establishment of collaborative networks has strengthened communication across different sectors, created an efficient value-service network, reduced resource waste, and improved the consumer experience.
The healthcare industry is fully embracing new technologies and actively pursuing digital transformation. Digital tools are connecting regulatory agencies, the pharmaceutical industry, pharmaceutical distribution and retail, healthcare services, payers, and patients, reimagining the foundational principles of healthcare system architecture and comprehensively advancing the development of the healthcare sector.
Pharmaceutical companies have begun to explore digital innovations in drug development and have formulated corresponding digital innovation strategies. Currently, the core of these digital innovations in drug development lies in leveraging artificial intelligence and cloud computing capabilities, vast amounts of patient-generated data, and ubiquitous digital devices, applying them to the following six areas:
(1) Application of Artificial Intelligence in the Structure-Activity Relationship Analysis of Compounds
(2) Application of Artificial Intelligence in Predicting Crystal Structures of Small-Molecule Drugs
(3) Informatization of Volunteer Recruitment
(4) Cloud-Based EDC and Remote Data Monitoring
(5) Wearable Devices Track Clinical Performance of New Drugs Post-Launch
(6) Patient Community
Artificial Intelligence Applied to Structure-Activity Relationship Analysis of Compounds.Structure-Activity Relationship (SAR) of drugs refers to the relationship between a drug's chemical structure and its pharmacological activity. Early SAR studies qualitatively inferred the relationship between the structures of physiologically active substances and their activities in an intuitive manner, thereby deducing the structure of target enzyme active sites and designing new active compounds. With the advancement of information technology, computer-assisted Quantitative Structure-Activity Relationship (QSAR) has become the primary direction of SAR research, and QSAR has also emerged as one of the important methods for rational drug design.
Many software programs are now available that can simulate the analysis of structure-activity relationships (SAR) of compounds on computers, predict their potential biological activity, and thereby enable targeted screening of compounds most likely to become drugs, significantly reducing the time required for drug discovery.
Application of Artificial Intelligence in Predicting Crystal Structure of Small-Molecule Drugs.Drug polymorphs are of paramount importance to pharmaceutical companies, as they not only determine the clinical efficacy of small-molecule drugs but also hold substantial patent value. In simple terms, drug polymorph patents are the most critical patents following compound patents for active pharmaceutical ingredients. They serve as a key strategic asset for originator companies to block or delay generic manufacturers from launching generic versions after the expiration of the underlying compound patents. Drug polymorph patents can extend patent protection by 2 to 6 years, which translates into billions of dollars in market value for blockbuster drugs. For generic drug manufacturers, successfully designing around polymorph patents enables them to launch their products immediately upon the expiration of the originator’s compound patents, thereby rapidly capturing market share through competitive pricing strategies.
By integrating artificial intelligence and cloud computing technologies, enterprises can efficiently and dynamically configure thousands of drug polymorph cores in the cloud, enabling the prediction of all possible polymorphs of a small-molecule drug within thirty days. This allows pharmaceutical companies to no longer worry about missing critical polymorphs due to the limited search space of experimental methods, thereby empowering them to more effectively address polymorph patent challenges from generic drug manufacturers.
Digitalization of Volunteer Recruitment.Online platforms enable the rapid dissemination of clinical trial recruitment information to a large patient population, facilitating the screening of eligible participants and significantly reducing the time and financial costs associated with patient recruitment. Furthermore, data collection via smart wearable devices minimizes the invasiveness of clinical trials, thereby enhancing participant comfort.
Cloud-Based EDC and Remote Data Monitoring.Pharmaceutical companies have begun to adopt Electronic Data Capture (EDC) systems to collect electronic case report forms from subjects. Multi-stage data analysis based on clinical trial data collection via EDC enables faster decision-making, allowing researchers to expand sample sizes and geographic coverage, adjust allocation ratios among different groups, re-estimate sample sizes, modify experimental arms, or terminate trials. Furthermore, for volunteers, EDC facilitates more timely feedback on adverse event data, thereby better safeguarding their health and well-being.
Wearable Devices Track the Clinical Performance of New Drugs Post-Launch.Regulatory requirements mandate continuous post-marketing surveillance of drugs. Ongoing clinical studies require sustained patient engagement to enable pharmaceutical companies to collect data from each participant. Digital medical devices facilitate long-term monitoring without driving up costs. For tracking serious adverse events, digital health devices can help pharmaceutical companies promptly identify early issues—problems that were never detected during clinical trials due to limited sample sizes. This allows companies to respond rapidly, ensuring patient safety and safeguarding corporate reputation.
The Role of Patient Communities.From the patient’s perspective, an increasing number of individuals with the same medical condition are congregating in online communities to discuss their illnesses. Patients frequently share, without restraint, information about factors that may influence their response to medications they are currently taking. In some active online communities, strong user bonds have been formed among patients, who are eager to help one another and willing to share data.
Digital innovation in pharmaceutical companies permeates the entire lifecycle of new drugs, from research and development to market launch, encompassing compound screening, preclinical trials, clinical trials, and post-marketing surveillance. The adoption of digital tools has enabled pharmaceutical companies to shorten the time-to-market for new drugs, facilitate large-scale, continuous clinical trials and post-marketing studies, and track patient feedback through patient communities, thereby optimizing operational workflows.
Following the launch of a new drug, it is essential to communicate drug information and treatment protocols to physicians, while also conducting patient education to maintain adherence. Even for medications that have been on the market for many years, continuous feedback from physicians is required to monitor clinical performance, thereby facilitating observations on new indications, combination therapies, and other developments. Digital pharmaceutical marketing refers to the use of digital tools to achieve these objectives.
Furthermore, since prescription drugs cannot be directly promoted or marketed to the general public, the industry commonly refers to their online marketing as “digital pharmaceutical marketing,” whereas the marketing of over-the-counter (OTC) drugs and health supplements is termed “digital advertising.”
Foreign pharmaceutical companies began experimenting with digital marketing at an early stage, with many establishing dedicated digital marketing departments. According to a survey previously released by Strategy&, the strategy consulting arm of PwC, which interviewed more than 150 senior executives from pharmaceutical companies in Europe and the United States, 90% of these companies have widely implemented or piloted digital tools as one of their marketing channels to deliver information and services related to diseases, products, cutting-edge academic technologies, and medical education.
Currently, major pharmaceutical companies primarily leverage digital tools to serve two key groups: physicians and patients. From the perspective of serving physicians, pharmaceutical companies choose digital tools for academic promotion and marketing mainly as a supplement to the traditional model of medical representative visits. By capitalizing on the advantages of low cost and diverse formats, these tools help establish more effective information communication platforms between pharmaceutical companies and physicians, who have demonstrated an optimistic and open attitude toward digital solutions. Furthermore, pharmaceutical companies can utilize digital tools to aggregate professional knowledge and resources, thereby establishing themselves as leaders in academic expertise.
In addition to fostering better engagement with physicians, another objective of digital marketing is to serve patients. For instance, leveraging internet-based tools to manage patient adherence after a physician has prescribed medication holds significant value for doctors, patients, and pharmaceutical companies. Due to market regulations and pharmaceutical compliance constraints, most patient education platforms are currently operated by third-party platform companies.
The popularity of digital marketing is primarily driven by two factors: first, its low cost. Compared to traditional methods such as visits by pharmaceutical sales representatives and participation in academic conferences, online marketing incurs lower expenses and consumes fewer human and material resources. Second, its extensive reach. The inherent characteristics of internet tools enable rapid replication and dissemination. Furthermore, with the implementation of policies in China such as tiered diagnosis and treatment and the strengthening of primary healthcare, pharmaceutical sales have become increasingly decentralized. In this context, online marketing helps pharmaceutical companies access broader markets.
From the perspective of specific channels, physician communities, physician tools, mobile health, and internet healthcare platforms are important channels for pharmaceutical companies’ digital marketing. Chronic disease management and health management apps have also gained favor among pharmaceutical companies. In addition to collaborating with third-party platforms, some pharmaceutical companies choose to build in-house teams to develop websites and apps, operate public accounts, and engage in other forms of online marketing.
Despite its significant potential and proven success stories, pharmaceutical digital marketing still lacks mature models and market feedback. Strategy&’s global survey reveals that 31% of respondents question the effectiveness of digital tools.
Although the traditional commercial marketing model of pharmaceutical representative visits is characterized by high costs and a relatively narrow target audience, it remains the most acceptable marketing approach for pharmaceutical companies and holds irreplaceable value in marketing. In contrast, digital marketing has not yet gained full industry recognition in practice; it is still in an exploratory phase, with no single model having achieved widespread acceptance or endorsement.
As an emerging and exploratory marketing model, digital marketing does not overturn existing marketing models; rather, it represents a new endeavor built upon established marketing frameworks and philosophies. Digital tools and platforms bridge the gap between pharmaceutical manufacturers, physicians, and patients, compressing communication channels to deliver information to target audiences with greater precision and convenience. By leveraging a suite of integrated tools, this approach aims to influence audience behavior, facilitating the transition from “awareness” to “action.”
The concept of “New Retail” in the pharmaceutical industry is not indigenous to the sector but was introduced from the e-commerce and retail domains. The Alibaba Group first proposed the “New Retail” concept and even established a dedicated business unit for it, underscoring its strategic importance. Alongside New Retail, Alibaba’s “Five News and One Fairness” strategy comprises New Manufacturing, New Technology, New Finance, New Energy, and a Fair Competitive Environment.
Alibaba posits that “New Retail” refers to a model integrating online and offline channels, merging services with products, and combining technology with data. This approach reconstructs the triad of “consumers, goods, and scenarios,” thereby enhancing supply chain efficiency and improving consumer experience. Following Alibaba’s lead, numerous e-commerce and retail enterprises have interpreted “New Retail,” enriching its conceptual framework and gradually extending its application to sectors such as pharmaceuticals and food service.
In the early stages, “Internet + Pharmaceutical New Retail” primarily referred to the online-to-offline (O2O) model in the pharmaceutical sector, including initiatives such as the Ali Health O2O Alliance, JD Daojia, Haoyaoshi, Dingdang Kuaiyao, and Kuaifang Songyao. Some fresh-food delivery platforms have also entered the pharmaceutical and healthcare market, becoming significant participants. Pharmaceutical new retail has met patients’ demands for convenient medication purchases and home delivery services; however, current product offerings remain largely concentrated on over-the-counter (OTC) drugs and health products, with prescription sources constituting a major limiting factor.
Major players in pharmaceutical distribution and retail have also begun to adopt the concept of new pharmaceutical retail. For instance, Shanghai Pharmaceuticals established Shangyao Cloud Health in March 2015, positioning it as an “Internet+” development platform for the new retail of prescription drugs. Shangyao Cloud Health’s business model centers on the electronic circulation of prescriptions, covering multiple stages including prescription acquisition and management, payment processing and rational use control, as well as fulfillment and delivery. This has created a new retail ecosystem for prescription drugs under the brand “Yiyao.”
In June 2015, Sinopharm Group established Sinopharm Online, a “supply chain + internet” platform for pharmaceuticals under its umbrella. Sinopharm Online is committed to building China’s most comprehensive new retail platform for pharmaceuticals in terms of product specifications, geographic coverage, and transaction volume. Sinopharm Distribution and Retail provide extensive category and regional coverage along with a robust quality system, and can collaborate with specific medical services to create an integrated “pharmaceutical new retail” platform.
The implementation of new retail in the pharmaceutical industry involves the use of a series of digital tools and platforms, such as apps under the O2O model, remote diagnosis and electronic prescription circulation platforms under the external prescription dispensing model, and SaaS services and B2B e-commerce platforms under the “Internet + Supply Chain” model.
The new retail model in the pharmaceutical industry also incorporates the concepts of DTP (Direct-to-Patient) pharmacies and smart pharmacies. The former refers to direct distribution by manufacturers of high-value drugs, led by the manufacturers themselves, making new specialty drugs and out-of-pocket medications more accessible to patients. The latter encompasses three scenarios: a model centered on intelligent management and scheduling of hospital pharmacies, supplemented by offline delivery, such as Kangmei Smart Pharmacy; a model focused on prescription information, emphasizing the circulation of prescription data to facilitate patient access to medications, such as WeChat’s “Smart Pharmacy” project; and a model primarily based on supply chain services, strengthening the drug supply capabilities of primary healthcare institutions and pharmacies, such as “Cloud Drug Warehouse” and “Cloud Pharmacy.”
The concept of new retail in the pharmaceutical sector has accelerated the fragmentation, restructuring, and integration of the pharmaceutical retail landscape. Pharmaceutical retail is transitioning from a model focused solely on product provision to one that combines “products + services.” In the future, as policies such as the separation of prescribing and dispensing are further implemented, new retail in the pharmaceutical industry will evolve toward deeper insights and more sophisticated business models. As the primary practitioners of this new retail paradigm, retail pharmacies will directly benefit from these developments.
In The Nature of Technology, W. Brian Arthur writes: “Technology has brought us comfortable lives and boundless wealth, and has fueled economic prosperity. In short, our world has been transformed by technology.”
This statement holds equally true for the pharmaceutical and healthcare industry: technology has brought boundless wealth to the sector, fueling its remarkable prosperity. The industry is continuously leveraging new technologies to innovate products and services, ensuring that everyone can access high-quality, convenient, and personalized healthcare. The adoption of digital tools is neither its starting point nor its endgame.
[Source Citation]
PwC Strategy&: The Current State and Reflections on Digital Marketing in Pharmaceutical Companies
VCBeat: Digital Innovation in Drug R&D
IBM Institute for Business Value: Digital Transformation in the Healthcare Industry